3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 1
3
Phase 2
2
Status
Active not recruiting
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
3
Tumor-Agnostic
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Carcinoma
4
NSCLC
3
Lung Neoplasms
3
Neoplasm Metastasis
2
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Non-small Cell Carcinoma
1
Neoplasms
1
Neoplasm, Residual
1
NSCLC Patients With Brain Metastasis
1
Locally Advanced or Metastatic Non-squamous NSCLC
1
Locally Advanced or Metastatic EGFR T790M+ NSCLC
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Bronchial Neoplasms
1
Brain Neoplasms
1
Anticancer Treatment
1
Interventions
Carboplatin
17
Cisplatin
14
Paclitaxel
12
Pemetrexed
11
pembrolizumab
9
Gemcitabine
7
Docetaxel
6
Sorafenib
5
osimertinib
4
durvalumab
4
130-nm albumin-bound paclitaxel
4
padeliporfin
3
cabozantinib
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Cetuximab
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
regorafenib
2
olaparib
2
Sunitinib
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Nivolumab
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma
×
osimertinib
×
Clear all
NCT06417814
2026-05-14
TROPION-Lung15
AstraZeneca
Phase 3
Recruiting
744 enrolled
NCT05261399
2026-04-06
SAFFRON
AstraZeneca
Phase 3
Active not recruiting
345 enrolled
NCT04035486
2025-10-10
FLAURA2
AstraZeneca
Phase 3
Active not recruiting
587 enrolled
44 charts
1 FDA
NCT04816214
2024-03-05
GEOMETRY-E
Novartis
Phase 3
Terminated
6 enrolled
20 charts